myelofibrosis Archives -

AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer

AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis

https://pharmaphorum.com/news/aacr-abbvie-says-mid-stage-trial-backs-navitoclax-in-myelofibrosis/

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

https://pharmaphorum.com/news/gsk-bolsters-cancer-pipeline-with-1-9bn-sierra-oncology-buy/

After turning down routine NHS funding of Bristol-Myers Squibb’s Inrebic for bone marrow disorder myelofibrosis earlier this year,

NICE changes tack on NHS use of BMS’ myelofibrosis drug Inrebic

https://pharmaphorum.com/news/nice-changes-tack-on-nhs-use-of-bms-myelofibrosis-drug-inrebic/

Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to

MorphoSys offers $1.7bn for Constellation, but investors see stars

https://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/

Shares in US biotech CTI BioPharma have shot up after the FDA agreed to an accelerated review early

CTI wins over FDA to claim early review of myelofibrosis drug

https://pharmaphorum.com/news/cti-wins-over-fda-to-claim-early-review-of-myelofibrosis-drug/

Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA

Celgene scores regulatory win ahead of BMS merger

https://pharmaphorum.com/news/celgene-scores-regulatory-win-ahead-of-bms-merger/

myelofibrosis